Research

Hormonal

GLP-1 receptor agonists increase the risk of gallbladder disease, including cholelithiasis and cholecystitis, through mechanisms involving cholecystokinin (CCK) suppression, altered bile acid receptor signaling (FXR/TGR5), and disrupted gut-brain pathways, leading to bile stasis and gallstone formation.

If you are taking a GLP-1 agonist (like semaglutide or liraglutide), be aware that you have a higher risk of gallbladder problems, especially if you are taking higher doses or losing weight rapidly. Watch for symptoms like severe abdominal pain, nausea, or fever, and report them to your doctor immediately. Your doctor may monitor you more closely or adjust your treatment plan to mitigate this risk.

GoodSupportsHIGH confidence
This review explores the potential mechanisms by which GLP-1RAs may contribute to biliary disease, focusing on the roles of cholecystokinin suppression, bile acid receptor signaling, and alterations in gut-brain pathways.
Mariana M. Ramírez‐Mejía et al. · Therapeutic Advances in Endocrinology and Metabolism · 2025

Why this rating

Supported by multiple meta-analyses and systematic reviews of RCTs cited in the paper, though some observational studies show conflicting results.

Source

GLP-1 receptor agonists and gallbladder disease risk: insights into molecular mechanisms and clinical implications

Mariana M. Ramírez‐Mejía et al. · Therapeutic Advances in Endocrinology and Metabolism · 2025

DOI 10.1177/20420188251406456

narrative_reviewCited 11×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →